Wolfe Research Downgrades Celldex Therapeutics to Peer Perform
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research has downgraded Celldex Therapeutics from Outperform to Peer Perform, indicating a less favorable outlook for the company's stock performance.
September 27, 2024 | 9:45 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wolfe Research has downgraded Celldex Therapeutics from Outperform to Peer Perform, suggesting a less optimistic view on the stock's potential performance.
The downgrade from Outperform to Peer Perform by Wolfe Research indicates a shift in the analyst's view on Celldex's stock, which could lead to a negative short-term impact on the stock price as investors react to the revised rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100